|Bid||80.15 x 1300|
|Ask||0.00 x 900|
|Day's Range||88.54 - 89.87|
|52 Week Range||73.69 - 89.87|
|PE Ratio (TTM)||83.84|
|Earnings Date||Jul 24, 2018|
|Forward Dividend & Yield||2.25 (2.57%)|
|1y Target Est||91.94|
Here is a look at the 10 biggest venture-backed IPOs and acquisitions from the first half of what has been a very active year for such exits.
INDIANAPOLIS, July 12, 2018 /PRNewswire/ -- Starting August 1, a new dedicated helpline called the Lilly Diabetes Solution Center will assist people who need help paying for their insulin – such as those with lower incomes, the uninsured, and people in the deductible phase of their high-deductible insurance plans, Eli Lilly and Company (LLY) announced today. A customized suite of solutions for all Lilly insulins, including for Humalog® (insulin lispro), will be used by helpline operators to find answers that best fit the personal circumstances of patients.
We want researchers to cure disease. But the honest truth is that you could potentially make a fortune by betting against drugmakers in this indication.
The last time we checked in with DnB, it had sold more than half of its investment in Intel. Norway’s largest and oldest private financial institution (established 1822) slashed its holdings in Intel (INTC) to 1.7 million shares from 3.8 million shares in the first quarter. DnB seemed to have a rethink in the second quarter, however, buying 537,300 more shares of the chip giant and raising its investment to 2.3 million shares as of June 30.
Pfizer (NYSE:PFE) was the target of a Presidential tweet tantrum Monday over its second price hike of the year but investors shrugged it off.
On Friday, Biogen (NASDAQ:BIIB) shares soared on news that one of its Alzheimer’s drug trials was showing tremendous promise. Specifically, BIIB stock jumped nearly 20% after an update on BAN-2401, a phase 2 drug that showed a statistically significant slowdown in the memory loss associated with Alzheimer’s. BAN-2401, an antibody that takes aim at the amyloid plaque in the brain that’s thought to be a key cause of Alzheimer’s, was cast into a questionable light late last year.
Incyte’s (INCY) product portfolio includes targeted therapies and immuno-therapies for oncology and non-oncology diseases. Incyte’s product portfolio includes 17 molecular targets and 19 clinical candidates. The chart below shows its revenues from collaborations since the first quarter of 2017.
Incyte Corporation (INCY) reported revenues of $382.3 million during the first quarter, a marginal decline in YoY (year-over-year) revenues compared to $384.1 million during the first quarter of 2017. These revenues include the product revenues from sales of Jakafi and Iclusig, royalty revenues from Jakavi and Olumiant, and milestone and contract revenues. The chart below compares the revenues for Incyte since the first quarter of 2017.
On July 6, Zoetis (ZTS) and Abaxis (ABAX) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
For the few drugmakers that haven’t given up on the decades-long, elusive quest for a cure of Alzheimer’s disease, each piece of news is a small signpost along a possible path to success -- and billions of dollars in potential sales. This is the story of Alzheimer’s. Dramatic ups and downs have been typical, with about 200 failed attempts to find a treatment. Drugmakers are seeking to escape a maze, trying one approach, failing, then starting over with another.
Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.
Leading US pharmaceutical company Eli Lilly (LLY) specializes in human pharmaceuticals and animal health. The chart below shows Eli Lilly’s revenue and EPS since Q1 2017, and analysts’ estimate for Q2 2018.
The US pharmaceutical sector comprises drug manufacturers, drug marketers, and biotechnology companies. The chart below lists some recent mergers and acquisitions in the sector.
Acadia Pharmaceuticals (ACAD) is a biopharmaceutical company engaged in developing and bringing to market innovative medicines targeted at central nervous system disorders. Of the eight analysts covering Acadia Pharmaceuticals in July, seven have given the stock “buy” or higher recommendations, while one has given it a “hold” rating. The mean rating for the stock is 2, and its target price is $47.29, implying a potential upside of 193% over the stock’s trading price of $16.13 on July 2.
Pfizer (NYSE:PFE) is a pharma/biotech dinosaur. This stock is a survivor of decades of stock market turmoils and corrections. It currently sits on a potential long-term technical breakout point on the monthly chart.
Eli Lilly (LLY) recently completed the acquisition of ARMO Biosciences (ARMO). It also announced several developments for its existing products as well as products in the pipeline. In this article, we’ll discuss LLY’s developments for June, which are illustrated in the chart below.
Wall Street analysts expect Eli Lilly’s (LLY) second-quarter adjusted earnings per share to reach $1.29 on revenues of $6.0 billion. This forecast represents 3.4% growth in revenues compared to $5.8 billion during the second quarter of 2017.
Elanco, which is Eli Lilly’s (LLY) animal health arm, comprises food animal products and companion animal products. Elanco reported revenues of ~$761.0 million during the first quarter, a 1.0% decline in YoY (year-over-year) revenues compared to ~$769.0 million during the first quarter of 2017. The chart below compares the revenues for Elanco since the first quarter of 2017.
Eli Lilly’s (LLY) cardiovascular products include Adcirca, Cialis, and Effient. The company’s cardiovascular product portfolio reported lower sales during the first quarter, which resulted from lower sales of these drugs. The chart below compares the revenues for key cardiovascular products since the first quarter of 2017.
LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want access to our free research report on Eli Lilly and Co. (NYSE: LLY) ("Eli Lilly"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=LLY as the Company's latest news hit the wire. On June 28, 2018, the Company declared that Taltz® (ixekizumab) met the primary and major secondary endpoints in COAST-W, which is a Phase-3 study evaluating Taltz® for the treatment of Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA). Active-Investors.com is currently working on the research report for Analogic Corporation (NASDAQ: ALOG), which also belongs to the Healthcare sector as the Company Eli Lilly.